跳至主要内容
临床试验/IRCT20211122053144N1
IRCT20211122053144N1招募中3 期

Investigating the effects of Silymarin in the treatment of idiopathic hyperbilirubinemia:a randomized,double-blind, placebo-controlled, clinical trial

Mashhad University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 days 至 10 days(—)
性别
All

入选标准

  • Term neonates who have the AAP criteria for the treatment of hyperbilirubinemia with phototherapy
  • Healthy term neonates who have jaundice from the 2nd to the 10th day of birth and need phototherapy

排除标准

  • Neonates with bilirubin level in range of blood exchange
  • The neonate or mother has received phenobarbital
  • Neonates with dehydration, sepsis, pneumonia, anemia, severe weight loss, hypoglycemia, renal failure, heart failure, possible hemolytic or inherited hemolytic disease, neonates with conjugated hyperbilirubinemia, neonates with G6PD, ABO or Rh incompatibility
  • Neonates with a history of jaundice medication from two days before

研究者

相似试验